Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q13438
UPID:
OS9_HUMAN
Alternative names:
Amplified in osteosarcoma 9
Alternative UPACC:
Q13438; A6NDD1; A6NFR7; A6NLB2; A8K5Q9; B4DE28; B4DPX1; B4E1I6; E7ENT8; E7EW91; F8VUH2; G3XA88; O00579; Q6IBL2; Q8IZ58; Q9BW99
Background:
Protein OS-9, also known as Amplified in osteosarcoma 9, plays a crucial role in the endoplasmic reticulum (ER) by ensuring quality control and facilitating the ER-associated degradation (ERAD) pathway. It is adept at recognizing and binding to terminally misfolded non-glycosylated proteins as well as improperly folded glycoproteins, retaining them in the ER, and potentially directing them towards ubiquitination and subsequent degradation. One of its known targets includes the TRPV4 protein.
Therapeutic significance:
Understanding the role of Protein OS-9 could open doors to potential therapeutic strategies. Its involvement in protein quality control and degradation pathways highlights its potential as a target for diseases caused by protein misfolding.